Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
A Single-center, Single-arm, Prospective Clinical Study on the Efficacy and Safety of Venetoclax and Azacitidine Combined With HAAG in the Induction Treatment of Intermediate and High-risk Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
60 participants
Feb 15, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of VA combined with HAAG in the induction treatment of newly diagnosed acute myeloid leukemia.
Eligibility
Inclusion Criteria8
- Newly diagnosed intermediate and high-risk AML according to the WHO (2022) classification of acute myeloid leukemia (non-APL).
- Age 18-65.
- ECOG score: 0-2.
- No history of previous chemotherapy or target therapy.
- Serum total bilirubin \<= 2 times the upper limit of normal (ULN), alanine aminotransferase (ALT) \<= 1.5 times ULN, aspartate aminotransferase (AST) \<=1.5 times ULN;
- Creatinine clearance rate \>=30 mL/min;
- Serum lipase \<= 1.5 times ULN, amylase \<= 1.5 times ULN;
- Capable to understand and willing to participate in this study, signed the informed consent form.
Exclusion Criteria10
- AML transformed with chronic myelogenous leukemia.
- Acute promyelocytic leukemia (type M3).
- Patients with a second malignancy requiring treatment.
- Patients with uncontrolled active infection.
- Patients with left ventricular ejection fraction \< 0.5 by echocardiography or grade III/IV cardiovascular dysfunction according to the New York Heart Association Classification.
- Patients with hepatic and renal inadequacy: total serum bilirubin \>=2.0 mg/dl, AST \>=3 times ULN, serum creatinine clearance (Ccr) \<50 ml / min.
- Patients with arterial oxygen saturation (SpO 2) was \<95%.
- Patients with HIV infection.
- Patients with active hepatitis B or hepatitis C infection.
- Patients with other commodities that the investigators considered not suitable for the enrollment.
Interventions
Venetoclax:100mg, qd, d1;200mg, qd, d2;400 mg, qd, d3\~10, per os; Azacitidine:75mg/m2/d, d1\~7, subcutaneous injection; Homoharringtonine:1mg/d, d4\~10, intravenous infusion; Aclarubicin:10mg/d, d4\~7, intravenous infusion; Cytarabine:10mg/m2,q12h,d4\~10, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06394011